Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
LYT-100 in Post-acute COVID-19 Respiratory Disease (Phase 2, Romania)
2020-003210-13Phase 2Active
- Sponsor
- PureTech Health
- Start
- Oct 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in post-COVID syndrome and coronavirus disease 2019 (COVID-19) comparing LYT-100 (Deupirfenidone) with Placebo (2 arms). Primary endpoint: Change in six-minute walk test distance (Part A). Started Oct 2020; status: active.
02
Drugs
deupirfenidone
03
Conditions
post-COVID syndromecoronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on 2020-003210-13.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2020-003210-13.